The story of aspirin and vascular disease starts with John O
Brien, a haematologist in Portsmouth in the 1960s, who reported
that the ingestion of 150mg of aspirin substantially reduced the
aggregation of platelets . On the basis of this finding, and the
assumption that the incidence of thrombosis would be reduced,
O’Brien persuaded the UK Medical Research Council in 1968 to
set up a randomised trial of aspirin .